$BCLI
Brainstorm Cell Therapeutics Inc

2016 Q3 Form 10-Q Financial Statement

#000114420416118186 Filed on August 11, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $850.0K $830.0K $570.0K
YoY Change -20.56% -16.16% -44.66%
% of Gross Profit
Research & Development $790.0K $151.0K $830.0K
YoY Change -47.33% -89.02% -49.39%
% of Gross Profit
Depreciation & Amortization $17.00K $22.00K $20.00K
YoY Change -15.0% -26.67% -33.33%
% of Gross Profit
Operating Expenses $1.640M $151.0K $1.400M
YoY Change -36.19% -89.02% -47.57%
Operating Profit -$983.0K
YoY Change -58.4%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $30.00K $20.00K $10.00K
YoY Change -200.0% -80.0% -116.67%
Pretax Income -$1.610M -$960.0K -$1.380M
YoY Change -38.08% -57.71% -49.45%
Income Tax
% Of Pretax Income
Net Earnings -$1.606M -$962.0K -$1.380M
YoY Change -38.3% -57.53% -49.45%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$86.28K -$51.47K -$74.35K
COMMON SHARES
Basic Shares Outstanding 18.65M shares 18.50M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.19M $11.48M $15.96M
YoY Change -34.75% -41.73% 86.89%
Cash & Equivalents $955.0K $944.0K $428.0K
Short-Term Investments $10.24M $10.54M $15.53M
Other Short-Term Assets $80.00K $70.00K $70.00K
YoY Change -33.33% -36.36% 133.33%
Inventory
Prepaid Expenses
Receivables $110.0K $1.270M $760.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $11.39M $12.81M $16.79M
YoY Change -37.04% -36.14% 74.91%
LONG-TERM ASSETS
Property, Plant & Equipment $310.0K $318.0K $271.0K
YoY Change 15.67% 12.77% -13.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $30.00K $341.0K $292.0K
YoY Change 1605.0% -12.31%
Total Long-Term Assets $330.0K $344.0K $292.0K
YoY Change 23.13% 13.53% -6.71%
TOTAL ASSETS
Total Short-Term Assets $11.39M $12.81M $16.79M
Total Long-Term Assets $330.0K $344.0K $292.0K
Total Assets $11.72M $13.15M $17.08M
YoY Change -36.16% -35.4% 72.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $350.0K $355.0K $1.169M
YoY Change 4.48% -52.98% -24.19%
Accrued Expenses $580.0K $652.0K $1.500M
YoY Change -74.87% -56.68% 11.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $1.200M $1.282M $2.952M
YoY Change -57.72% -49.25% -5.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.200M $1.282M $2.952M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.200M $1.280M $2.952M
YoY Change -57.72% -49.33% -8.78%
SHAREHOLDERS EQUITY
Retained Earnings -$72.89M -$70.14M
YoY Change 10.19% 13.77%
Common Stock $84.75M $84.27M
YoY Change 23.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.53M $11.87M $14.13M
YoY Change
Total Liabilities & Shareholders Equity $11.72M $13.15M $17.08M
YoY Change -36.16% -35.39% 72.33%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q4
OPERATING ACTIVITIES
Net Income -$1.606M -$962.0K -$1.380M
YoY Change -38.3% -57.53% -49.45%
Depreciation, Depletion And Amortization $17.00K $22.00K $20.00K
YoY Change -15.0% -26.67% -33.33%
Cash From Operating Activities -$270.0K -$1.410M -$1.290M
YoY Change -89.33% -14.55% -35.82%
INVESTING ACTIVITIES
Capital Expenditures $11.00K $59.00K -$20.00K
YoY Change -8.33% -468.75% -71.43%
Acquisitions
YoY Change
Other Investing Activities $300.0K $200.0K $910.0K
YoY Change -84.62% -137.74% -133.83%
Cash From Investing Activities $290.0K $130.0K $900.0K
YoY Change -85.05% -123.64% -132.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 110.0K
YoY Change -100.0% 120.0%
NET CHANGE
Cash From Operating Activities -270.0K -1.410M -1.290M
Cash From Investing Activities 290.0K 130.0K 900.0K
Cash From Financing Activities 0.000 0.000 110.0K
Net Change In Cash 20.00K -1.280M -280.0K
YoY Change -103.39% -41.55% -94.07%
FREE CASH FLOW
Cash From Operating Activities -$270.0K -$1.410M -$1.290M
Capital Expenditures $11.00K $59.00K -$20.00K
Free Cash Flow -$281.0K -$1.469M -$1.270M
YoY Change -88.95% -10.1% -34.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
283000 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18653922 shares
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
6675000 USD
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
109000 USD
CY2015 bcli Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
2000 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-8488000 USD
CY2015 bcli Exercise And Reissuance Of Warrants Value
ExerciseAndReissuanceOfWarrantsValue
12409000 USD
CY2015 bcli Exercise Of Liability Classified Warrants
ExerciseOfLiabilityClassifiedWarrants
145000 USD
CY2015 bcli Exercise Of Equity Classified Warrants
ExerciseOfEquityClassifiedWarrants
2333000 USD
us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
31000 USD
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
38000 USD
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
47000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
7000 USD
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-856000 USD
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
200000 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-814000 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-787000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
668000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
465000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3587000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4387000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-962000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-2265000 USD
CY2016Q2 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
22000 USD
CY2015Q2 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
24000 USD
CY2015Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
321000 USD
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
74000 USD
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-67000 USD
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
67000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70141000 USD
CY2016Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
341000 USD
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.24
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
84258000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17080000 USD
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
318000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2620000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
14128000 USD
CY2016Q2 us-gaap Assets
Assets
13154000 USD
CY2015Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
21000 USD
CY2015Q4 us-gaap Assets
Assets
17080000 USD
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
355000 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1169000 USD
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
292000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1137000 USD
CY2016Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
652000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1658000 USD
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1500000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1948000 USD
CY2016Q2 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
275000 USD
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-43000 USD
us-gaap Net Income Loss
NetIncomeLoss
-2752000 USD
us-gaap Net Income Loss
NetIncomeLoss
-4501000 USD
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.15
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1282000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2952000 USD
CY2016Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
84754000 USD
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-72893000 USD
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
11872000 USD
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13154000 USD
CY2016Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
23000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2950000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2213000 USD
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
465000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
31000 USD
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
499000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2795000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-4568000 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18290343 shares
CY2015 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
108000 USD
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
835000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
108000 USD
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-671000 USD
CY2015Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1650000 USD
bcli Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
P15Y
CY2016Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2015Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
108000 USD
CY2016Q2 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
768000 USD
CY2015Q2 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-362000 USD
CY2016Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
262000 USD
CY2016Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
CY2015Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
12000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3494000 USD
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2015Q2 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2193000 USD
CY2016Q2 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
CY2015Q2 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
CY2016Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
11481000 USD
bcli Percentage Of Royalty Paymentif Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentifLicensedProductCoveredByValidClaimOrOrphanDrugStatus
0.05 pure
CY2016Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1406000 USD
us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
-4990000 USD
us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
14104000 USD
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1301000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4251000 USD
CY2016Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
59000 USD
CY2015Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-16000 USD
CY2016Q2 us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
-196000 USD
CY2015Q2 us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
539000 USD
CY2016Q2 bcli Investment In Lease Deposit
InvestmentInLeaseDeposit
0 USD
CY2015Q2 bcli Investment In Lease Deposit
InvestmentInLeaseDeposit
0 USD
CY2016Q2 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
137000 USD
CY2015Q2 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-555000 USD
CY2016Q2 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
CY2015Q2 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
12000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1269000 USD
bcli Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
0.03 pure
us-gaap Maturity Of Time Deposits
MaturityOfTimeDeposits
P3M
CY2015 us-gaap Maturity Of Time Deposits
MaturityOfTimeDeposits
P6M
CY2016Q2 us-gaap Share Based Compensation
ShareBasedCompensation
262000 USD
CY2009Q4 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
74667 shares
us-gaap Share Based Compensation
ShareBasedCompensation
668000 USD
CY2015Q2 us-gaap Share Based Compensation
ShareBasedCompensation
321000 USD
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
CY2016Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.05
CY2015Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.12
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18654040 shares
dei Entity Registrant Name
EntityRegistrantName
BRAINSTORM CELL THERAPEUTICS INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001137883
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
988000 USD
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q2 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-21000 USD
CY2015Q2 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-98000 USD
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18450464 shares
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-983000 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2363000 USD
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Stock Issued1
StockIssued1
0 USD
CY2016Q2 us-gaap Stock Issued1
StockIssued1
0 USD
CY2016Q2 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
0 USD
CY2015Q2 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
0 USD
CY2014Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-15
CY2015Q2 us-gaap Stock Issued1
StockIssued1
0 USD
dei Trading Symbol
TradingSymbol
BCLI
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18654040 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18654040 shares
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18654040 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18643288 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18643288 shares
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
151000 USD
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1375000 USD
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
800000000 shares
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
832000 USD
CY2015Q2 bcli Noncash Financing Activities
NoncashFinancingActivities
0 USD
bcli Noncash Financing Activities
NoncashFinancingActivities
0 USD
bcli Noncash Financing Activities
NoncashFinancingActivities
130000 USD
CY2016Q2 bcli Noncash Financing Activities
NoncashFinancingActivities
0 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
46600000 USD
bcli Proceeds From Issuances Of Common Stock Through Equity Warrants And Options Exercises
ProceedsFromIssuancesOfCommonStockThroughEquityWarrantsAndOptionsExercises
0 USD
bcli Proceeds From Issuances Of Common Stock Through Equity Warrants And Options Exercises
ProceedsFromIssuancesOfCommonStockThroughEquityWarrantsAndOptionsExercises
2348000 USD
CY2016Q2 bcli Proceeds From Issuances Of Common Stock Through Equity Warrants And Options Exercises
ProceedsFromIssuancesOfCommonStockThroughEquityWarrantsAndOptionsExercises
0 USD
CY2015Q2 bcli Proceeds From Issuances Of Common Stock Through Equity Warrants And Options Exercises
ProceedsFromIssuancesOfCommonStockThroughEquityWarrantsAndOptionsExercises
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
0 USD
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
0 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 85.05pt" align="justify"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="clear:both;WIDTH: 100%; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 56.7pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="76"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 28.35pt; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top" width="38"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>D.</font></b></div> </td> <td style="BORDER-BOTTOM: #d4d0c8; BORDER-LEFT: #d4d0c8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; BORDER-TOP: #d4d0c8; BORDER-RIGHT: #d4d0c8; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Use of estimates</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: -28.35pt; MARGIN: 0in 0in 0pt 85.05pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 85.05pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name View Source Status
0001144204-16-118186-index-headers.html Edgar Link pending
0001144204-16-118186-index.html Edgar Link pending
0001144204-16-118186.txt Edgar Link pending
0001144204-16-118186-xbrl.zip Edgar Link pending
bcli-20160630.xml Edgar Link completed
bcli-20160630.xsd Edgar Link pending
bcli-20160630_cal.xml Edgar Link unprocessable
bcli-20160630_def.xml Edgar Link unprocessable
bcli-20160630_lab.xml Edgar Link unprocessable
bcli-20160630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v445016_10q.htm Edgar Link pending
v445016_ex31-1.htm Edgar Link pending
v445016_ex31-2.htm Edgar Link pending
v445016_ex32-1.htm Edgar Link pending
v445016_ex32-2.htm Edgar Link pending